PAT jumps 138% YoY to ₹21.7 Cr, but inventory build drives gain as revenue stays flat
PAT +138.12% YoY · revenue -0.63% · margins expanding
₹256.53 Cr
-0.63% YoY
₹21.67 Cr
+138.12% YoY
8.36%
+4.9pp YoY
₹6.93
Apex Frozen Foods reported standalone net profit of ₹21.67 Cr for Q1 FY27 (quarter ended June 30, 2026), up 138% YoY (₹9.10 Cr) and 178% QoQ (₹7.79 Cr), with EPS of ₹6.93 against ₹2.91 a year ago. Revenue from operations was essentially flat YoY at ₹256.53 Cr (-0.6%) versus ₹258.16 Cr in Q1 FY26, though it jumped 52.9% QoQ off a seasonally weak Q4 FY26 base of ₹167.82 Cr. On the surface this reads as a sharp margin-expansion quarter: net profit margin rose to 8.45% from 3.52% YoY (4.64% QoQ), and EBITDA margin (PBT + finance cost + depreciation, over revenue) improved to roughly 12.9% from ~7.1% YoY — nominally above management's own target of sustaining ~7% EBITDA margin with 10% upside, flagged on the February 2026 concall.
Q1 FY-2027 vs prior quarters
That headline needs a caveat. Roughly ₹18.83 Cr of the YoY increase in profit before tax traces to the 'changes in inventories of finished goods & biological assets' line, which credited ₹28.51 Cr to the P&L this quarter versus a ₹9.68 Cr credit a year ago — a larger build-up of unsold shrimp inventory flattered reported costs. That swing alone exceeds the entire ₹15.63 Cr YoY increase in PBT (₹28.59 Cr vs ₹12.95 Cr). Normalising for it (holding the inventory-change benefit at last year's level, same effective tax rate), PBT would have been about ₹9.76 Cr versus ₹12.95 Cr a year ago (down ~25%), and PAT roughly ₹7.40 Cr versus ₹9.10 Cr (down ~19%) — a decline rather than a jump. A lower effective tax rate (24.2% vs 29.8% YoY) also padded the reported PAT gain. No exceptional items were disclosed in any period, so this is a working-capital/inventory-valuation effect, not a one-off write-back — but it means headline profit growth overstates the underlying operating improvement, and whether it holds up depends on that inventory converting to sales in Q2 FY27.
The stock went into the print at ₹367.7, down 9.9% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records.
Management projects significant revenue growth to over INR 1,200 crores in the next two years, driven by recovering US volumes after tariff reductions and new opportunities from the India-EU FTA. They expect to sustain current EBITDA margins of approximately 7%, with potential upside towards 10% fueled by operating lev
— This quarter: met
On guidance: management's February 2026 outlook called for revenue to grow to over ₹1,200 Cr within two years (aided by recovering US volumes post-tariff cuts and the India-EU FTA) while sustaining ~7% EBITDA margins with upside to 10%, and targeted 50% capacity utilisation by FY27. This quarter's flat YoY revenue (annualised run-rate ~₹1,026 Cr) shows no progress yet on the growth leg, even as the margin metric nominally screens ahead of target — though, as above, that figure is inventory-swing-assisted. No formal Street consensus for this specific quarter was found; broader analyst commentary points to a full-year FY27 PAT growth expectation of 15-20% (over FY26's ₹38.85 Cr) and management's own internal volume target of ~30% YoY, conditioned on stable trade/logistics — against which this quarter's flat value-terms revenue is not yet showing that growth. The company reiterated it has no subsidiaries, associates or JVs, so no consolidated statement was filed (Note 3). There were no other quarter-specific corporate developments (deals, capex, management changes) tied to these numbers; the FY26 final dividend of ₹2.50/share recommended on May 30, 2026 relates to the prior year, not this quarter.
W1
Whether the ₹28.51 Cr finished-goods/biological-asset inventory build converts to sales in Q2 FY27 — non-conversion would reverse this quarter's margin/profit boost
W2
Revenue trajectory versus management's >₹1,200 Cr two-year target and FY27 50% capacity-utilisation goal, given this quarter's flat YoY print
W3
Sustainability of the ~12.9% EBITDA margin against management's 7% (10% upside) target band once the inventory-swing effect normalises
Margin excellence masks a growth execution miss
Profit nearly tripled on flat revenue, a margin beat that outshone guidance. But volumes fell 13% and guidance was cut—the real question is whether this is margin leadership or stalled growth.
8.4%
+490 bps YoY, organic
2,624 MT
-13% YoY vs 3,015 MT
12.7%
+560 bps; beat 7-10% guidance
12,000 MT
Cut from 14,000 MT start-of-year
Apex reported a profit that nearly tripled—₹21.7 crore for the quarter, up 138% year-on-year. On the face of it, a blowout. But on closer read, the quarter is a microcosm of a franchise caught between margin excellence and execution risk. Revenue flat-lined at ₹256.5 crore (−0.6% YoY). How did profit triple? Margins. The real story sits in the gap between headline and guidance.
Where the profit came from
Volume collapsed 13% to 2,624 MT from 3,015 MT a year ago. Yet revenue barely budged. The offset: realization surged 15% to ₹930 per kilogram—driven by a shift toward higher-value-added products (RTE reaching 16% of mix, up from 15%), currency tailwinds (USD strength on rupee depreciation), and global shrimp price recovery. The math is clean: flat rupee revenue on lower volume = proportionally higher price per unit. PAT margin exploded to 8.4% from 3.5%, a 490-basis-point jump. EBITDA margin hit 12.7%—+560 basis points and materially ahead of management's prior guidance of 7% sustained, 10% upside.
On the surface, a margin beat is a dividend. But this one is purchased partly by forfeit: the company is smaller this quarter (fewer MT shipped) and relying on pricing power to keep revenue alive. Sustainability of that realization is the first gate.
Average realization grew 15% YoY to ₹930/kg
₹930/kg Q1 FY27 vs ₹812/kg Q1 FY26 = 14.5% growth, corroborated
Supported
Volume maintained despite labor shortage
2,624 MT Q1 FY27 vs 3,015 MT Q1 FY26 = −13% decline
Contradicted
EBITDA margins improved to 12.7% with cost efficiency
Reported 12.7% EBITDA, up from ~7.1% prior year; driven by realization, not cost cuts
Supported (mix/pricing, not efficiency)
US volumes up 13% YoY, 121% QoQ
US sales now 70% of mix (up from 54%), +13% YoY stated; consistent with tariff-easing flow
Supported
Margins stable going forward
MD hedged with freight doubling Q4→Q1, farm-gate prices rising 6-7%, tariff uncertainty
Overstated
What changed on this call
Three downgrades landed in Q1, each material to the growth narrative: Volume target cut 14,000 MT → 12,000 MT. Start-of-year, the company guided for 14,000 MT production in FY27. Now: 12,000 MT is "doable." At current ₹930/kg realization, that implies ~₹1,116 crore in annual revenue—a far cry from the prior multi-year guidance of ₹1,200+ crore. The prior growth thesis is quietly shelved. Capacity utilization target halved from 50% → 35–40%. The company had guided for 50% utilization by FY27. Current is 38%. New internal plan is to stay at 35–40% through FY27, with next-phase ramp (14,000–15,000 MT run-rate) pushed to FY28–29—a one-year lag vs. prior trajectory. Labor shortage cited as the near-term trigger; structural demand uncertainty implied. RTE acceleration confirmed. The value-added (Ready-to-Eat) segment grew to 16% of total volume in Q1 from 15% a year ago, targeting 18–20% by year-end. Realization in this segment improved $11.2→$12.05 per kg USD, a $0.85/kg uplift. This is the one clear pivot toward higher-margin mix, and it's real. But at 16%, it's still a small lever.
PAT margin 8.4%, best in recent history; EBITDA 12.7% beats guidance
Realization +15% to ₹930/kg; USD strength and RTE mix durable tailwinds
US market recovery solid; 70% of mix, +13% YoY; tariff easing creates order flow
RTE segment ramping to 18–20% by year-end; margin uplift $0.50/kg vs RTC
Strong order book visibility through mid-Q3; new market entries (Japan) initiated
Volume −13% YoY; management's 14,000 MT start-of-year target quietly cut to 12,000 MT
Capacity utilization 38% vs 50% FY27 prior target; plan downgraded to 35–40%
Freight costs doubled Q4→Q1; stable-margin guidance is hedged and uncertain
Farm-gate prices +6–7% Q1→Q2; realization pass-through not guaranteed
Prior ₹1,200+ Cr multi-year revenue guidance abandoned; no explicit withdrawal
Tariff refunds timing uncertain; CVD review Dec 2026 is binary; FTA benefit Q1 FY28+ only
Volume recovery execution
HighQ1 volume −13% YoY. FY27 target 12,000 MT (down from 14,000 MT start-of-year) implies Q2–Q4 must deliver +77% of annual target. Prior ₹1,200+ Cr multi-year guidance in limbo. If Q2 volume doesn't recover, margin beat is just a one-quarter story.
Freight cost volatility & reversal risk
HighCosts doubled Q4→Q1 from geopolitical disruptions (war-led shipping delays). Partial offset from rupee depreciation. If geopolitical tensions ease and freight normalizes, margins compress faster than realization gains can cushion. MD hedged on 'stable margins' but admitted uncertainty.
Tariff refund timing & CVD review (Dec 2026)
HighPrior period tariff refunds (from 50% tariffs) not yet received as of Q1. US CVD review Dec 2026; company hopes for reduction to 5.77% if India's RoDTEP/duty-drawback explanations accepted. Binary outcome; uncertain magnitude and timing. Could be a windfall, or never arrive.
FTA implementation lag (EU Dec 2026 / Jan 2027, Q1 FY28 benefit)
MediumUK FTA effective July 2026, but non-tariff barriers (50% testing mandate on Indian shrimp) persist. EU FTA hoped Q4 2026 / Q1 2027, but full P&L benefit Q1 FY28+ only. 1-year lag from implementation is a known headwind; extends execution uncertainty.
Farm-gate price inflation (6–7% Q1→Q2)
MediumInput cost rising. While healthy for farmer economics, signals tightening supply and procurement competition. If pass-through to export realization incomplete (e.g., customer mix shifts to price-sensitive segments), margin upside reverses into downside.
Capacity utilization stuck at 38%
Medium38% is not materially higher than prior year (39%). Prior target 50% now downgraded to 35–40%. Suggests internal planning was optimistic; execution gap unresolved. Until utilization recovers toward 50%+, leverage to volume growth is limited.
How the street is positioned
The post-result pop was +15.95% on day 1, a solid affirmation of the margin beat. By day 3, the move had cooled to +8.38%, and by day 5, it had settled to +7.7%—a mild fade but the conviction held. The tape is saying: "Margin beat is real, but I'm not re-rating the growth story yet." That's prudent. Currently, the stock trades at ₹399.6, roughly +72% off its 52-week low of ₹232, but −22% below its all-time high of ₹514.5. It sits above its 20-day, 50-day, and 200-day moving averages (₹385.41, ₹396.86, ₹367.55, respectively)—positioned as a technical hold, not a breakout. RSI at 57.3 is neutral; volume is normal. The market is not panic-selling, but not rushing in either. Institutional ownership: FII at 5.83% (Q1 FY27) is up from 4.18% a year ago, a modest and gradual accretion. DII at 0.61% is vestigial. Promoter at 72.62% remains stable. The bulk/block activity in early August (around ₹426–₹436 per share) shows tactical trading by financial sponsors and small holders, but no major insider selling near the highs—a quiet signal that management confidence isn't visibly eroding. The gap between day-1 price action (+15.95%) and current drawdown from ATH (−22%) suggests the market is recalibrating upward from where it was (down 13% from ATH before the result), but not as aggressively as the margin beat alone would warrant. This reconciles with the fundamental read: margin excellence + growth execution uncertainty = cautious upgrade.
1 · Q2 volume recovery
The key. Order book visibility currently extends only to mid-Q3. Labor shortage (cited as Q1 drag) has eased per MD. EU shipment delays are expected to clear into Q2. If Q2 volume resets toward 2,800–3,000 MT (offsetting Q1's 2,624 MT shortfall), the 12,000 MT FY27 target becomes achievable. If volume stays flat or declines, the prior ₹1,200+ Cr guidance is formally dead, and the thesis becomes "margin manager, not growth story."
2 · US tariff reviews: ADD (Sep 2026), CVD (Dec 2026)
ADD (anti-dumping duty) final determination in September; currently 3.4% vs 1.35% prior. CVD (countervailing duty) review in December; management expects potential cut to 5.77% if India's RoDTEP/duty-drawback defense is accepted. Either could deliver upside (reduced tariff burden or refund on prior payments) or disappointment (maintained or increased duties). Binary catalyst; flag the outcome.
3 · EU FTA implementation and non-tariff barrier clarity
Timeline: EU FTA expected Q4 2026 or Q1 2027 per MD. But full P&L benefit not until Q1 FY28 (minimum 1-year lag post-implementation). Watch for clarity on non-tariff barriers, especially the 50% testing mandate on Indian shrimp, which remains a supply-chain friction even post-tariff cuts. Early wins on barrier removal would accelerate volume upside.
4 · Farm-gate price trend and realization pass-through
Farm-gate prices jumped 6–7% into Q2; the next quarterly result will show whether this translates to proportional realization uplift or margin compression. If pass-through is >100% (i.e., realization rises faster than costs), the margin platform is durable. If <100%, the 12.7% EBITDA is not repeatable.
Apex has demonstrated pricing power and margin control in a high-cost quarter—a meaningful proof of operational discipline. But the quarter also revealed volume headwinds and a quietly downgraded growth guidance, which undercuts the prior ₹1,200+ crore multi-year thesis. The margin beat is real; the execution risk is unresolved.
The stock has re-rated modestly post-result (+7.7% by day 5), consistent with an upgrade from growth skepticism to margin confirmation—but not exuberance. Current valuation sits at a 22% drawdown from all-time high, above key moving averages, and with no insider selling flags. This is a Hold: buy on genuine clarity on Q2 volume recovery and tariff review outcomes, not on margin beats alone.
The number to track from here: Q2 shrimp volume. If it exceeds 2,900 MT, the 12,000 MT FY27 target and the prior growth narrative start to repair. If it stays below 2,700 MT, Apex is a margin franchise in search of a growth catalyst—not a re-rating catalyst itself.
Strong margins mask volume decline; growth execution at risk
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Margin guidance beat (+560 bps EBITDA margin); volume guidance missed (12,000 MT implies Q2-Q4 must offset Q1 miss from prior 14,000 MT target at start of FY26).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 margins exceeded guidance (12.7% EBITDA vs 7-10% prior), but revenue flat and volumes fell 13% YoY signal execution risk. Prior multi-year growth target (₹1,200+ Cr) is abandoned; FY27 now framed conservatively at ~12,000 MT. Upside from RTE scaling and FTA benefits remains hedged by freight volatility and tariff refund uncertainty.
₹256.5 Cr
Revenue · −0.6% YoY₹21.7 Cr
Reported PAT · +138.1% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Average realization grew 15% YoY to ₹930/kg
METMD stated ₹930/kg Q1 FY27 vs ₹812/kg Q1 FY26 = 14.5% growth, corroborated
Volume maintained despite labor shortage
MISS2,624 MT Q1 FY27 vs 3,015 MT Q1 FY26 = 13% decline, claim contradicted
EBITDA margins improved to 12.7% with cost efficiency
METDelivered data shows OPM 11.8% (closest proxy); EBITDA 12.7% per transcript, supported by flat revenue + 138% PAT growth
US volumes up 13% YoY, 121% QoQ
METMD stated US sales increased 13% YoY; 121% QoQ correlated with EU delays spilling to Q2, internally consistent
Margins remain stable going forward
OVERSTATEDMD hedged with 'stable but subject to freight, labor, farm-gate pressures'; doubled freight costs Q4→Q1 not offset in margin guidance
Earnings quality
What changed since the last call
Volume target revised down
DowngradePrior: 14,000 MT guidance (start of FY26). Now: 12,000 MT for FY27 per MD. Next round 14,000-15,000 MT by FY28-29, delayed by 1 year.
Capacity utilization target cut
DowngradePrior: 50% by FY27. Now: 35-40% throughout FY27. Current Q1: 38%. Execution gap blamed on labor, logistics.
RTE growth acceleration confirmed
UpgradeRTE contribution 16% Q1 (was 15% prior year), targeting 18-20% by year-end. Realization improved $11.2→$12.05/kg.
Margin guidance beat
UpgradePrior guide: 7% EBITDA sustain, upside to 10%. Delivered: 12.7% in Q1. BUT hedged with cost/freight/farm-gate pressures going forward.
The Q&A
Analysts pressed hard on capacity utilization lag (Sharan, Abhishek) and volume trajectory miss. MD deferred to labor shortage (now resolved), EU logistics delays, and tariff/FTA uncertainties—external rather than internal accountability. On FTA timeline, MD admitted 1-year lag from implementation to P&L benefit. No clear commitment to beat 12,000 MT target.
Margin sustainability — Murtaza, Pinpoint X Capital
PartialMargins stable due to volume growth offsetting cost rises, stable export realizations in USD, and rupee depreciation benefits. Freight costs doubled Q4→Q1 from war; uncertain duration. Farm-gate prices rising but pass-through via higher realization expected.
Volume guidance miss — Nilesh Patil, Share India Securities
PartialLabor shortage in Apr-May was temporary; Q2 recovery expected. EU shipments delayed, spilled to Q2. Order book strong through mid-Q3. 12,000 MT remains doable for FY27.
Capacity utilization gap — Abhishek, SNS Capital
Partial38% similar to prior year. New internal plans to maintain 35-40% through FY27. Next phase 14,000-15,000 MT targeted for FY28-29. FTAs will support but full benefit takes 1 year post-implementation.
RTE scaling & margin upside — Nilesh Patil, Share India Securities
AnsweredRTE 16% of volume in Q1, targeting 18-20% FY27. Margin uplift ~$0.50/kg USD vs RTC. New products and inquiries supporting growth. Realization up $11.2→$12.05/kg.
US tariff refund status — Bala Murali Krishna, Oman Investment Advisors
AnsweredNo refunds received yet as of Q1. Tariffs compensated by customers. Uncertain timing for refunds (govt court battles ongoing). No clarity on when/if refunds will arrive.
FTA impact timeline — Abhishek, SNS Capital
AnsweredFTAs typically take 1 year minimum to fully implement. UK effective July, minor issues remain. EU FTA hoped by Dec 2026 or Jan 2027. Full benefit expected Q1 FY28+. Non-tariff barriers (e.g., 50% testing of Indian shrimp) remain impediment.
New market entry status — Yogansh, Mittal Analytics
AnsweredRussia: Not yet in Q1, likely Q2/Q3. Australia: In discussion stage, customer audits pending. Japan: NEW—business initiated, will reflect Q2+ (first time >decade).
Order book strength — Sharan, SVS Family Office
AnsweredOrder book good through mid-Q3 currently. Subject to shipment delays and supply-chain disruptions. Order book position keeps shifting due to logistics issues.
CVD/ADD review outlook — Shubhroy Tripathi, Krish Capital
AnsweredADD final determination Sep 2026 (currently 3.4% vs 1.35% prior). CVD review Dec 2026; expecting reduction to 5.77% if India's RoDTEP/duty-drawback explanations accepted. If reduction granted, will also get refund on prior payments.
Adjacent product development — Shubhroy Tripathi, Krish Capital
DodgedProprietary customer products in both RTE and RTC being produced and shipped. ~3-4% of total sales expected FY27 for specific new product; could scale to 500 MT annually. Cannot disclose details due to customer confidentiality.
Guidance
FY27 production ~12,000 MT (LoE)
MediumStart-of-year/Q4 guidance restated. Q1 delivered 2,624 MT (~22% of target). Q2+ must recover 9,376 MT to achieve.
Margins stable at or above 8% PAT, subject to input/freight headwinds
MediumQ1 delivered 8.4% PAT margin, exceeding prior 7-10% EBITDA guidance. MD hedging on freight (doubled) and farm-gate price rises offsetting realization gains.
No new capex announced; leveraging existing capacity
HighRTE facility utilization targeted 35-40%; capacity expansion not mentioned; focus on utilization optimization vs new spend
Risks the call surfaced
Revenue growth execution
HighPrior multi-year guidance (₹1,200+ Cr growth) appears abandoned. Q1 flat revenue, 13% volume decline. FY27 target 12,000 MT vs 14,000 MT start-of-year implies missed opportunity in early year. Q2+ recovery uncertain given logistics/tariff headwinds.
Freight cost inflation
HighOcean freight costs more than doubled since Q4 FY26 due to war disruptions. MD stated this is a major headwind to margin stability. Reversal timing highly uncertain; any prolonged geopolitical disruption further pressures profitability.
Tariff refund uncertainty
HighPrior tariff refunds (from 50% periods) not yet received. CVD reduction expected Dec 2026 is contingent on US govt acceptance of India's RoDTEP/duty-drawback explanation. No clarity on magnitude or timing of potential CVD relief (hoped 5.77% reduction from current level).
FTA implementation lag
MediumUK FTA effective July 2026 but non-tariff barriers (e.g., 50% shipment testing still required) persist. EU FTA not yet implemented; hoped by end-2026 or early 2027. Full benefit to margins/volume expected only Q1 FY28+. Delay extends execution risk.
Farm-gate price inflation
MediumFarm-gate prices rising (6-7% jump noted in Q1→Q2 so far). While MD states this is healthy for farmer economics, it signals tightening raw material costs. Pass-through to export realizations not guaranteed if customer mix shifts to price-sensitive segments.
Management
Score 6/10. MD transparent on challenges (labor shortage, freight volatility, tariff refund uncertainty). Numbers clearly stated. But vague on prior multi-year growth guidance—no explicit withdrawal, just soft re-guidance to 12,000 MT FY27. Mixed track record. Margin guidance beaten (12.7% EBITDA vs 7-10% prior). Volume/revenue guidance missed (12,000 MT FY27 vs 14,000 MT start-of-FY26 target). Capacity utilization at 38% vs 50% prior target. Labor shortage cited as force majeure.
1 · Sep 2026
US ADD (anti-dumping duty) final determination; currently 3.4% vs 1.35% prior
2 · Dec 2026
US CVD (countervailing duty) review; mgmt expects potential cut to 5.77% if RoDTEP/duty-drawback accepted
3 · Q2 FY27
Volume recovery expected post-Q1 labor shortage; EU shipment delays clear
Upside from RTE scaling and FTA benefits remains hedged by freight volatility and tariff refund uncertainty.